AR037771A1 - Moleculas pequenas para el tratamiento del crecimiento celular anormal - Google Patents

Moleculas pequenas para el tratamiento del crecimiento celular anormal

Info

Publication number
AR037771A1
AR037771A1 ARP020104778A ARP020104778A AR037771A1 AR 037771 A1 AR037771 A1 AR 037771A1 AR P020104778 A ARP020104778 A AR P020104778A AR P020104778 A ARP020104778 A AR P020104778A AR 037771 A1 AR037771 A1 AR 037771A1
Authority
AR
Argentina
Prior art keywords
small molecules
treatment
cell growth
abnormal cell
erbb2
Prior art date
Application number
ARP020104778A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR037771A1 publication Critical patent/AR037771A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Moléculas pequenas que son útiles en el tratamiento del crecimiento celular anormal, tal como el cáncer, en mamíferos. Procedimiento de uso de tales moléculas pequenas en el tratamiento del crecimiento celular anormal en mamíferos, especialmente en seres humanos, y a composiciones farmacéuticas que contienen tales compuestos. Pequenas moléculas que son selectivas para el receptor erbB2 respecto al receptor erbB1, teniendo dicho inhibidor de erbB2 un intervalo de selectividades por erbB2 respecto a erbB1 entre 50-1500.
ARP020104778A 2001-12-12 2002-12-10 Moleculas pequenas para el tratamiento del crecimiento celular anormal AR037771A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34109101P 2001-12-12 2001-12-12

Publications (1)

Publication Number Publication Date
AR037771A1 true AR037771A1 (es) 2004-12-01

Family

ID=23336198

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104778A AR037771A1 (es) 2001-12-12 2002-12-10 Moleculas pequenas para el tratamiento del crecimiento celular anormal

Country Status (29)

Country Link
US (1) US20030171386A1 (es)
EP (1) EP1465632A1 (es)
JP (1) JP4181502B2 (es)
KR (1) KR20040063948A (es)
CN (1) CN1602195A (es)
AP (1) AP2004003058A0 (es)
AR (1) AR037771A1 (es)
AU (1) AU2002339687A1 (es)
BR (1) BR0214499A (es)
CA (1) CA2469670A1 (es)
DO (1) DOP2002000545A (es)
EA (1) EA200400680A1 (es)
EC (1) ECSP045146A (es)
GT (1) GT200200273A (es)
HR (1) HRP20040529A2 (es)
HU (1) HUP0501069A2 (es)
IL (1) IL161908A0 (es)
IS (1) IS7233A (es)
MA (1) MA27154A1 (es)
MX (1) MXPA04004107A (es)
NO (1) NO20042882L (es)
OA (1) OA12734A (es)
PA (1) PA8561301A1 (es)
PE (1) PE20030760A1 (es)
PL (1) PL373848A1 (es)
TN (1) TNSN04111A1 (es)
TW (1) TW200301121A (es)
WO (1) WO2003049740A1 (es)
ZA (1) ZA200404264B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
BR0317433A (pt) * 2002-12-18 2005-11-16 Pfizer Prod Inc Derivados bicìclicos para o tratamento do crescimento celular anormal
JP2006512355A (ja) * 2002-12-19 2006-04-13 ファイザー・プロダクツ・インク E−2−メトキシ−n−(3−{4−[3−メチル−4−(6−メチルピリジン−3−イルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−アリル)−アセトアミドの複合体、それらの製造方法および使用
BRPI0413745A (pt) * 2003-08-18 2006-10-24 Pfizer Prod Inc horário mde dosagem para agentes anticancerìgenos erbb2
EP2612853A1 (en) * 2003-09-26 2013-07-10 Exelixis Inc. c-Met modulators and methods of use
CN1921864A (zh) * 2003-12-24 2007-02-28 西奥斯公司 使用TGF-β抑制剂治疗神经胶质瘤
UA85706C2 (en) * 2004-05-06 2009-02-25 Уорнер-Ламберт Компани Ллси 4-phenylaminoquinazolin-6-yl amides
GB0417107D0 (en) * 2004-07-30 2004-09-01 Wellcome Trust The Genes II
EP1896451A2 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Bicyclic derivatives for the treatment of abnormal cell growth
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JPWO2008072634A1 (ja) 2006-12-12 2010-04-02 武田薬品工業株式会社 縮合複素環化合物
MX2009007610A (es) 2007-02-06 2009-07-24 Boehringer Ingelheim Int Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW200944528A (en) 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc N-(4-{〔6,7雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽及其結晶型
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
RU2614254C2 (ru) 2011-08-31 2017-03-24 Дженентек, Инк. Диагностические маркеры
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2017003668A1 (en) 2015-07-01 2017-01-05 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
JP2023512174A (ja) 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング HER2阻害薬としての[1,3]ジアジノ[5,4-d]ピリミジン
JP2023512175A (ja) * 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング HER2阻害薬としての[1,3]ジアジノ[5,4-d]ピリミジン
CN113429390B (zh) * 2020-03-23 2022-04-15 苏州恩华生物医药科技有限公司 喹唑啉衍生物及其应用
US11608343B2 (en) * 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
EP1192151B1 (en) * 1999-07-09 2007-11-07 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
AU778588B2 (en) * 1999-10-19 2004-12-09 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
EE200200710A (et) * 2000-06-22 2004-06-15 Pfizer Products Inc. Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production

Also Published As

Publication number Publication date
EP1465632A1 (en) 2004-10-13
PA8561301A1 (es) 2003-12-30
JP2005527486A (ja) 2005-09-15
BR0214499A (pt) 2005-05-10
IL161908A0 (en) 2005-11-20
CN1602195A (zh) 2005-03-30
PE20030760A1 (es) 2003-09-05
GT200200273A (es) 2003-10-03
OA12734A (en) 2006-06-28
HRP20040529A2 (en) 2004-10-31
ZA200404264B (en) 2005-08-31
US20030171386A1 (en) 2003-09-11
ECSP045146A (es) 2004-07-23
EA200400680A1 (ru) 2005-06-30
MA27154A1 (fr) 2005-01-03
DOP2002000545A (es) 2003-06-16
NO20042882L (no) 2004-07-07
AU2002339687A1 (en) 2003-06-23
IS7233A (is) 2004-04-26
HUP0501069A2 (en) 2006-06-28
PL373848A1 (en) 2005-09-19
TW200301121A (en) 2003-07-01
CA2469670A1 (en) 2003-06-19
WO2003049740A1 (en) 2003-06-19
AP2004003058A0 (en) 2004-06-30
KR20040063948A (ko) 2004-07-14
MXPA04004107A (es) 2004-07-23
JP4181502B2 (ja) 2008-11-19
TNSN04111A1 (fr) 2006-06-01

Similar Documents

Publication Publication Date Title
AR037771A1 (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
PA8680701A1 (es) Derivados de oxindol
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
ECSP066406A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
PA8643201A1 (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
CO4560552A1 (es) Antagonistas de receptores de taquicininas no peptidicos
BRPI0514474A (pt) multiparticulados
UY27732A1 (es) Uso de análogos del benzimidazol en el tratamiento de la proliferación celular.
NI200800060A (es) Bencimidazoles sustituidos como inhibidores de cinasa.
UY28731A1 (es) Compuestos quimicos
AR049915A1 (es) Compuestos con contenido de boro y metodos de uso de los mismos
CL2009000448A1 (es) Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros.
UY27894A1 (es) Derivados de cinamida.
UY29685A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
UY27452A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
UY29109A1 (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas
UY29925A1 (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure